CohBar (OTCPK:CWBR) - Stock Price, News & Analysis

CWBR Stock Overview

CohBar, Inc. es una empresa biotecnológica en fase clínica que desarrolla terapias basadas en mitocondrias y péptidos para el tratamiento de enfermedades crónicas y relacionadas con la edad.

About the company

CWBR fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Risk Analysis

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

No tiene una capitalización bursátil significativa ($2M)

Cotización muy volátil en los últimos 3 meses

Los últimos informes financieros tienen más de 6 meses

CohBar, Inc. Competitors

TC Biopharm (Holdings)

NasdaqCM:TCBP

US$2.2m

Histogen

OTCPK:HSTO

US$2.1m

Salarius Pharmaceuticals

NasdaqCM:SLRX

US$2.1m

Galmed Pharmaceuticals

NasdaqCM:GLMD

US$2.0m

Price History & Performance

Summary of all time highs, changes and price drops for CohBar
Historical stock prices
Current Share Price	US$0.77
52 Week High	US$6.90
52 Week Low	US$0.58
Beta	1.59
1 Month Change	0.63%
3 Month Change	3.38%
1 Year Change	-57.70%
3 Year Change	-98.02%
5 Year Change	-99.01%
Change since IPO	-98.17%

Recent updates

Shareholder Returns

	CWBR	US Biotechs	US Market
7D	-13.1%	-4.3%	-0.8%
1Y	-57.7%	3.9%	25.9%

Rentabilidad frente al sector: CWBR obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 6.3%.

Rentabilidad vs. Mercado: CWBR obtuvo unos resultados inferiores a los del mercado US, que fue del 22.5% el año pasado.

Price Volatility

Is CWBR's price volatile compared to industry and market?
CWBR volatility
CWBR Average Weekly Movement	22.7%
Biotechs Industry Average Movement	12.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de CWBR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: CWBRha disminuido de 35% a 17% en el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2007	10	n/a	https://www.cohbar.com

CohBar, Inc, empresa biotecnológica en fase clínica, desarrolla terapias basadas en mitocondrias y péptidos para el tratamiento de enfermedades crónicas y relacionadas con el envejecimiento. Desarrolla el CB4211, una terapéutica que se encuentra en ensayos clínicos de fase 1a/1b para el tratamiento de la esteatohepatitis no alcohólica y la obesidad; y los análogos CB5138, que están en estudio preclínico para tratar la fibrosis pulmonar idiopática y otras enfermedades fibróticas. CohBar, Inc. se constituyó en 2007 y tiene su sede en Menlo Park, California.

CohBar, Inc. Fundamentals Summary

How do CohBar's earnings and revenue compare to its market cap?
CWBR fundamental statistics
Market cap	US$2.22m
Earnings (TTM)	-US$12.69m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.2x

P/E Ratio

Is CWBR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CWBR income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$12.69m
Earnings	-US$12.69m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.36
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did CWBR perform over the long term?

See historical performance and comparison

CWBR Stock Overview

Rewards

Risk Analysis

CohBar, Inc. Competitors

NasdaqCM:TCBP

US$2.2m

OTCPK:HSTO

US$2.1m

NasdaqCM:SLRX

US$2.1m

NasdaqCM:GLMD

US$2.0m

Price History & Performance

Recent News & Updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Recent updates

CohBar, Inc.(OTCPK:CWBR) dropped from S&P TMI Index

CohBar, Inc.(OTCPK:CWBR) dropped from NASDAQ Composite Index

CohBar Expects the Trading in its Common Stock to be Suspended Upon the Opening of Business on November 29, 2023 and Nasdaq to File Form 25-NSE with the SEC to Formally Delist CohBar's Common Stock

Morphogenesis, Inc. cancelled the acquisition of CohBar, Inc. (NasdaqCM:CWBR) in a reverse merger transaction.

New major risk - Share price stability

Morphogenesis, Inc. and Cohbar, Inc. Announce Positive Results from Phase 1B Trial of Ifx-Hu2.0, A Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma and Cutaneous Squamous Cell Carcinoma

Morphogenesis, Inc. entered into a definitive agreement to acquire CohBar, Inc. (NasdaqCM:CWBR) for approximately $130 million in a reverse merger transaction.

High number of new and inexperienced directors

CohBar, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CohBar stock gains on 1-for-30 reverse stock split

CohBar, Inc. to Report Q2, 2022 Results on Aug 15, 2022

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Here's Why We're Watching CohBar's (NASDAQ:CWBR) Cash Burn Situation

CohBar Announces Extension of Nasdaq Compliance Period

CohBar, Inc. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$2.17

High number of new and inexperienced directors

CohBar, Inc., Annual General Meeting, Jun 15, 2022

High number of new and inexperienced directors

Price target decreased to US$5.63

Independent Director recently bought US$96k worth of stock

CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 Under Development for NASH and Obesity

High number of new directors

CohBar, Inc. Provides Update on the Phase 1a/1b Clinical Trial for CB4211 Under Development for NASH and Obesity

CohBar, Inc.(NasdaqCM:CWBR) dropped from Russell 3000E Index

CEO & Director Steven Engle has left the company

Price target decreased to US$6.10

CohBar appoints Joseph Sarret as CEO and Director

CohBar, Inc. Announces the Selection of CB5138-3

New 90-day high: US$1.65

CohBar, Inc. Announces Preclinical Collaboration with NIAID to Evaluate Potential of CB5064 Analogs for Treatment of COVID-19 ARDS

CohBar collaborates with NIAID for CB5064 analogs in COVID-19-related ARDS

New 90-day high: US$1.54

CohBar, Inc. Confirms Efficacy of Novel Apelin Agonists in Acute Respiratory Distress Syndrome Model

New 90-day high: US$1.21

CohBar EPS in-line

CohBar, Inc. to Report Q3, 2020 Results on Nov 16, 2020

CohBar (CWBR) Investor Presentation - Slideshow

CohBar, Inc. Announces New Preclinical Data Demonstrating That Combination of A Cb5138 Analog with nintedanib

CohBar, Inc. has completed a Composite Units Offering in the amount of $15.006 million.

New 90-day low - US$1.36

CohBar, Inc. to Report Q2, 2020 Results on Aug 13, 2020

New 90-day low - US$1.46

Shareholder Returns

Price Volatility

About the Company

CohBar, Inc. Fundamentals Summary

0.0x

-0.2x

Earnings & Revenue